Actively Recruiting
Randomized Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Intravenous CS-1103 After Fentanyl Challenge With Naloxone Blockade in Healthy Adults
Led by Clear Scientific, Inc. · Updated on 2026-08-24
16
Participants Needed
1
Research Sites
10 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, and efficacy of CS-1103, a drug given by intravenous infusion, in healthy adults aged 18 to 55. The study specifically looks at how CS-1103 behaves when administered after a clinically relevant dose of fentanyl, with naloxone used to block fentanyls effects. This phase 2 trial aims to understand CS-1103s effects in the presence of fentanyl overdose conditions. Participants are randomly assigned to one of two groups. One group receives an intravenous naloxone blockade, followed by fentanyl, and then placebo saline. The other group receives the same naloxone and fentanyl doses, followed by a single intravenous dose of CS-1103 at 1,000 mg. The study uses a quadruple-blind design, meaning participants, care providers, investigators, and outcomes assessors do not know who receives which treatment. During the study, participants are monitored closely for adverse events through physical exams, electrocardiograms, vital signs, and laboratory tests over 3 days plus a follow-up on day 10. Blood and urine samples are collected to measure CS-1103 and fentanyl concentrations over 48 hours. Researchers also assess effects on heart rhythm intervals and naloxone levels. The study involves healthy volunteers with prior opioid experience and includes detailed safety and pharmacokinetic evaluations.
CONDITIONS
Brief Title
A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
Research Team
A
Anna Del Rosario, B.S.
P
Piercen Oliver, Ph.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here